Explorez tous les épisodes du podcast RealPharma: Conversations with Pharma Pathfinders
| Titre | Date | Durée | |
|---|---|---|---|
| Cracking the Code on Patient Engagement: Conversational AI with Dan Fox | 05 May 2025 | 00:45:44 | |
🎙️ RealPharma Podcast Episode Title: Cracking the Code on Patient Engagement: Conversational AI with Dan Fox 🗓️ Release Date: May 5, 2025 🎧 Hosts: Dr. Na-Ri Oh & Ian Wendt 🎤 Guest: Dan Fox, Managing Director of Healthcare at Drips Episode Summary:In this eye-opening episode, we welcome Dan Fox, a trailblazer in AI-powered patient communication, to explore how proactive outreach and conversational AI are reshaping healthcare engagement. As the Managing Director of Healthcare at Drips, Dan shares how his team is using SMS-based AI to boost patient adherence, improve outcomes, and build trust—even in the face of complex compliance and tech fluency challenges. From personalized text reminders that get 60–80% response rates to thoughtful strategies for integrating AI without sacrificing patient experience, Dan takes us deep into what’s working (and what’s not) in healthcare communication today. Plus, he shares what excites him most about the future—including AI therapists, ambient scribes, and closing the tech adoption gap in health systems. 🔑 Key Topics Covered:
“We’re not using generative AI in our consumer outreach—because every single word needs to be approved. But we use AI to scale natural conversations.” – Dan Fox “Trust is everything. We use personalization and omnichannel context to build it—one message at a time.” – Dan Fox “We don’t want PHI. We just want to start the right conversation.” – Dan Fox 📘 Resources Mentioned:
Available wherever you get your podcasts—Spotify, Apple Podcasts, Amazon Music, and more.
| |||
| Healthcare Leadership and Resilience with Grace Magedman | 21 Apr 2025 | 00:45:31 | |
In this powerful and deeply human episode of RealPharma, we’re joined by Grace Magedman, PharmD—former Chief Pharmacy Officer at Children’s Hospital of Orange County, functional medicine practitioner, and founder of The Magidman Group. Grace takes us inside her 20+ years of hospital pharmacy leadership, where she navigated high-stakes medication decisions, complex implementation of rare disease therapies, and the ethical strain of resource constraints. But her most transformative leadership moment came not in the boardroom—but in her own experience of burnout. Now a certified high-performance coach, Grace shares how she rebuilt from the inside out, creating the Functional Resilience Framework—a science-based system that blends neuroscience, functional medicine, and leadership development to help others sustain performance without sacrificing purpose. Whether you’re in pharma, hospital leadership, or simply navigating the demands of high-impact work, Grace’s insights offer a roadmap to lead with clarity, energy, and longevity. 📌 Resources & Links:
| |||
| AI Recap - Andree Bates Episode Review | 04 Nov 2024 | 00:13:11 | |
In this latest episode of RealPharma, we’re diving back into the fascinating world of AI in pharma, breaking down all the insights from our conversation with the brilliant Andree Bates! If you missed it or want to catch the highlights, this episode serves up a concise, punchy summary covering everything from predictive analytics to patient outcomes and beyond. But there's a twist. Our hosts, this time, bring a unique, fresh perspective to the conversation—you might notice something different about how they tackle the topic. Stick around until the end, and you’ll find out what makes this episode truly special. Curious? You won’t want to miss this one. Tune in, share your thoughts, and see if you can guess what’s up!
Resources
| |||
| Mastering Omnichannel: Insights with Philip Vyt | 21 Oct 2024 | 00:54:52 | |
In this episode, Dr. Na-Ri Oh and Ian Wendt sit down with Philip Vyt, a renowned expert in omnichannel strategy and founder of Shyft, a consultancy specializing in omnichannel approaches for biopharma. They delve into the key concepts behind omnichannel and its distinction from multichannel, emphasizing the centrality of healthcare professionals (HCPs) in engagement strategies. Philip breaks down the importance of personalized content delivery and the role of interconnected channels in creating a 360-degree view of HCP interactions. He also shares practical advice for biopharma companies—both large and small—on building effective omnichannel campaigns, starting with "minimal viable campaigns" to learn by doing. The conversation explores the challenges companies face, such as managing content supply chains and the integration of technology, while highlighting the significant investments needed in marketing technology (MarTech) for a truly effective omnichannel approach. Philip also discusses the differences between the U.S. and European markets in terms of data privacy and consent, as well as the evolving role of AI and automation in real-time engagement with HCPs. Throughout, Philip provides actionable insights on how companies can avoid common pitfalls, emphasizing a focus on execution and the importance of aligning marketing with commercial excellence. Listeners will gain a deeper understanding of what it takes to implement a successful omnichannel strategy and why it’s a journey that requires commitment, adaptation, and collaboration across teams.
Resources: | |||
| Staying Ahead In Your Pharma Career with Kristiaan Rawlings | 07 Oct 2024 | 00:44:31 | |
In this episode, Dr. Na-Ri and Ian Wendt welcome back Kristiaan Rawlings, from EPM Scientific to discuss the latest trends in pharma and biotech hiring. They explore the key drivers of hiring, the impact of AI and advanced analytics, and the evolving expectations of candidates. Kristiaan emphasizes the importance of change agents in the industry and shares insights on the optimistic outlook for small biotechs and oncology. The conversation also touches on strategies for candidates to navigate career transitions and for companies to attract top talent in a competitive market.
Resources: | |||
| Opioid Epidemic: Michael Barnes on the Fight to End the Crisis | 23 Sep 2024 | 00:51:45 | |
In this episode, Ian Wendt and Dr. Na-Ri Oh interview Michael C. Barnes, Chairman of the Center for US Policy, about the US opioid crisis. They discuss the evolution of US policy on opioids, the impact of the crisis on different communities, the role of legislation and harm reduction, the accountability of the pharmaceutical industry, barriers to accessing treatment, and the importance of advocacy in addressing stigma. The conversation explores various themes related to the substance use disorder crisis, including the lack of parity in insurance plans, the role of prescribers, the need for treatment and support, the potential for decriminalization, the economic impact of substance use disorders, and the US-centric nature of the problem. The guests discuss the importance of addressing substance use disorder as a health condition and providing therapeutic responses and harm reduction services. They also highlight the need for policies that focus on prevention, access to treatment, and economic opportunities for individuals in recovery. The conversation emphasizes the complexity of the issue and the need for comprehensive solutions. Resources: | |||
| Medical Affairs Reimagined: Danny McBryan on Shaping Pharma’s Future | 09 Sep 2024 | 00:49:16 | |
Danny McBryan, an executive leader in the pharmaceutical industry, discusses the evolving role of medical affairs in healthcare. He highlights the importance of medical affairs in conveying the science of pharmaceutical companies and translating complex data into a meaningful narrative for healthcare providers, payers, patients, and policymakers. McBryan emphasizes the need for medical affairs to be seen as a strategic partner rather than a support function and advocates for closer collaboration between medical affairs, health economics, and outcomes research (HEOR) to demonstrate the value of drugs and address unmet needs. He also discusses the impact of digital transformation on medical affairs, including wearables, therapeutic digital solutions, social media, data analysis, and real-world evidence. McBryan envisions a future where medical affairs plays a more strategic role, engages with patients, and contributes to drug discovery and development.
RESOURCES | |||
| Empowering the Patient Voice: A Deep Dive into Advocacy with Stacey Tinianov | 26 Aug 2024 | 00:49:26 | |
In this episode, Na-Ri and Ian interview Stacey Tinianov, an independent patient advocate and founder of Advocates for Collaborative Education. They discuss the importance of patient advocacy, the role of digital health, and the future of patient engagement. Stacey shares her personal journey into patient advocacy and highlights the gaps in knowledge and understanding she experienced as a breast cancer survivor. She emphasizes the need for human-centered design in healthcare, where patients are at the center of the design, development, and deployment of programs and technologies. Stacey also discusses the impact of digital platforms on patient engagement and the importance of building relationships and engaging with patients beyond a transactional level. Patient advocacy is a multifaceted field that encompasses various areas, including clinical trial advocacy, research advocacy, and policy advocacy. The future of patient advocacy lies in the expansion of voices and the focus on improving quality of life and survivorship. Advocates play a crucial role in shaping clinical trials, ensuring patient-reported outcomes are considered, and driving policy changes. The ultimate goal is to achieve true partnerships between advocacy and industry, as well as the decentralization of clinical trials. Patient advocates can effectively communicate by understanding their motivation and goals and tailoring their language to resonate with different stakeholders. The consequences of not getting patient advocacy right include a regression to the frustrating relationship patients had with pharmaceutical companies in the past. However, progress has been made, and patient advocacy has the potential to drive positive change in healthcare.
Resources: | |||
| AI Revolution: Transforming Biopharma with Andree Bates | 12 Aug 2024 | 00:51:28 | |
Summary Dr. Andrée Bates, a pioneering force in the realm of artificial intelligence within the pharmaceutical industry, shares insights on the evolving role of AI in pharma, the future of healthcare innovation, and her advocacy for women in leadership. She discusses the early days of AI in pharma, the challenges faced, and the evolution of AI terminology. Dr. Bates also explores the application of AI in commercial insights and analytics, market access, drug discovery, and clinical trials. The conversation covers a wide range of topics related to the application of AI in the biopharma industry, including the use of synthetic data, digital twins, regulatory and medical affairs, market access, precision doctor targeting, and ethical implications. Dr. Andree Bates shares insights on the impact of AI on drug discovery, clinical trials, and patient care, as well as the potential for AI to revolutionize the industry.
Resources | |||
| Unmasking PBMs: Antonio Ciaccia Exposes the Hidden Power Players in Healthcare | 29 Jul 2024 | 00:57:27 | |
Summary In this episode, Dr. Na-Ri Oh and Ian Wendt discuss Pharmacy Benefit Managers (PBMs) and their impact on drug pricing and patient access to medications. They are joined by Antonio Ciaccia, CEO of 46 Brooklyn Research and president of 3 Access Advisors, which provides insights into the role of PBMs in the drug supply chain. The conversation highlights the consolidation of power among the top three PBMs, their anti-competitive behaviors, and the need for increased scrutiny and regulatory measures. The discussion also explores the distorted incentive structures that favor high-cost drugs over lower-cost alternatives, leading to higher drug costs and limited access for patients. The conversation explores the impact of pharmacy benefit managers (PBMs) on drug costs and access to medications. The report states that PBMs control about 70% of all specialty drug revenue, leading to the closure of independent retail pharmacies in rural areas. The conversation emphasizes the need for transparency and accountability in the PBM industry. It also discusses the potential solutions, including market-based approaches and policy changes, to address the inefficiencies and anti-competitive behaviors of PBMs. Resources | |||
| 340B Controversy: Who Really Benefits from Drug Discounts? | 17 Jul 2024 | 01:00:54 | |
In this episode, Dr. Na-Ri Oh and Ian Wendt discuss the 340B drug pricing program with guest William Sarraille, a healthcare law expert. They explore the origins of the program and its intended purpose. However, the program has grown exponentially and is now the second largest drug program in the country. Bill raises concerns about the lack of transparency and accountability in the program, as well as the impact on patients. He argues that the program should focus on delivering value to patients and ensuring that they benefit from the discounts. The conversation delves into the complexities and challenges of the 340B program, highlighting issues such as the patient definition, transparency, contract pharmacies, and the allocation of funds. The discussion considers the need for a more comprehensive and transparent system that ensures the benefits of the program flow to the patients. They also explore the possibility of implementing a claims data process that provides faster payment and greater certainty for both manufacturers and 340B entities. The conversation concludes with a reflection on the importance of leadership and collaboration in finding solutions to the program's problems.
Resources: | |||
| From Biotech Breakthroughs to Food Tech Revolution: Dr. Ron Shigeta’s Journey | 01 Jul 2024 | 01:00:16 | |
Summary Dr. Ron Shigeta, a pioneer in the biotech startup ecosystem, shares his insights and experiences in this episode. He discusses the success of IndieBio, a biotech accelerator that demonstrated the potential of modest investments in fueling biotech innovations. Dr. Shigeta also highlights the importance of timing, luck, and having a clear vision in the biotech industry. He explains the differences between synthetic biology and pharma startups and the challenges and opportunities they present. Additionally, he discusses the factors he considers when evaluating startup opportunities and the mindset of successful entrepreneurs. Finally, he shares his perspective on managing risk in biotech startups and the personal transition of becoming a startup CEO. In this conversation, Ron Shigeta discusses the landscape of venture capital funds and startup incubators, highlighting the importance of fund size and check-writing capabilities. He also explains his attraction to the food industry and the deep structural biology of food. The convergence of food and biotech is explored, with a focus on consumer applications and health-related applications. Ron shares different strategies for innovation and offers advice for aspiring entrepreneurs. He discusses promising areas for transformational impact, including the golden age of biology and the future of food and sustainability.
Chapters 00:00 Introduction to Dr. Ron Shigeta 01:31 Dr. Shigeta's transition from scientist to biotech startup figure 05:19 The impact of IndieBio's small investment model 08:43 The economics of biotech startups 09:57 Different pathways in biotech: synthetic biology vs. pharma 13:42 Factors in evaluating startup opportunities 14:09 The mindset of successful entrepreneurs 19:35 The importance of company vision and team dynamics 22:23 Managing risk in biotech startups 27:28 The personal transition of becoming a startup CEO 31:23 The risk tolerance of entrepreneurs 32:36 Venture Capital Funds and Startup Incubators 37:15 The Attraction of the Food Industry 42:30 Convergence of Food and Biotech 46:12 Innovation in Biotech and Pharma 49:37 Different Strategies for Innovation 51:42 Advice for Aspiring Entrepreneurs 53:47 Promising Areas for Transformational Impact 01:01:26 The Golden Age of Biology 01:04:51 The Impact of Whole Foods Conference 01:08:49 The Future of Food and Sustainability
Resources: | |||
| Bridging the Gap in Cancer Care Part 2: Dr. Yaming Wang on Innovation, Access, and the Power of Knowledge | 17 Mar 2025 | 00:48:24 | |
In this second part of our deep dive into hematology and oncology, we welcome back Dr. Yaming Wang, founder of Alphabet Health LTD and an expert in molecular oncology, pharmaceutical strategy, and medical education. Building on our previous discussion, we explore cutting-edge advancements in cancer diagnostics and therapies, including the promise and limitations of liquid biopsies, the evolution of immunotherapy, and the expanding role of CAR-T and antibody-drug conjugates. But innovation alone isn’t enough—how do we ensure these breakthroughs reach the patients who need them most? We tackle the challenges of healthcare communication, provider education, and patient access, examining how AI, public health initiatives, and systemic change can bridge the gap between scientific progress and real-world impact. Join hosts Dr. Na-Ri Oh and Ian Wendt for an engaging and thought-provoking conversation that not only highlights the science behind cancer treatment but also the urgent need to make these life-saving therapies more widely accessible. Don't miss this critical discussion on the future of oncology! | |||
| From the Forest to your Pharmacy: Dr. Steven King’s Ethnobotanical Journey | 17 Jun 2024 | 00:48:23 | |
In this enlightening episode of the RealPharma Podcast, hosts Ian Wendt and Dr. Nari Oh sit down with Dr. Steven King, a luminary in the field of ethnobotanical research and sustainable pharmaceutical development. Dr. King, currently serving as the Chief Sustainable Supply, Ethnobotanical Research, and IP Officer at Jaguar Health, shares his remarkable journey from a young adventurer in the Amazon rainforest to a pioneering figure in the integration of traditional botanical knowledge with modern medicine. Join us as we delve into the fascinating world of ethnobotany, exploring how Dr. King's lifelong passion for plant-based healing has led to groundbreaking developments in the pharmaceutical industry. Discover the story behind the Croton lechleri tree, popularly known as the Dragon's Blood tree, and how its unique properties have been harnessed to create an FDA-approved medication derived from this Amazonian marvel. Dr. King offers insights into his early experiences living with indigenous communities in South America, learning about their traditional uses of plants for medicine, and the ethical considerations involved in bringing these ancient practices into the global market. We discuss the importance of sustainability and respectful collaboration with local communities, emphasizing the crucial balance between conservation and commerce. This episode also touches on the broader implications of Dr. King’s work, from his contributions to the Healing Forest Conservatory to the role of bioethics in the commercialization of traditional knowledge. As the conversation unfolds, we explore the exciting future of plant-based therapeutics and the potential for ethnobotanical research to address some of the most pressing health challenges of our time. Tune in for a captivating discussion that spans decades of exploration, scientific discovery, and cultural exchange, highlighting how ancient wisdom can inform and transform modern healthcare.
Chapters 00:00 Introduction to Ethnobotany 02:04 Biocultural Diversity and Pharmaceutical Development 13:20 The Croton lechleri Tree and its Medicinal Uses 15:59 Ethnobotanical Research vs. Traditional Drug Development 21:39 Intellectual Property and Benefit-Sharing 24:27 Ethical and Sustainable Practices in Working with Indigenous Communities 28:27 Respecting Indigenous Knowledge and Rights in Plant-Based Medicine Development 34:03 The Financial Benefits of Commercializing Plant-Based Drugs for Indigenous Communities 36:23 The Potential Therapeutic Applications of Psychedelic Research
Resources: | |||
| Command the Room: Dr. Laura Sicola’s Strategies for Executive Communication Excellence | 03 Jun 2024 | 01:09:50 | |
Command the Room: Dr. Laura Sicola's Strategies for Executive Communication Excellence Hosts: Dr. Na-Ri Oh and Ian Wendt In this episode of the Real Pharma Podcast, we delve into the intricacies of effective executive communication with Dr. Laura Sicola, a renowned expert in leadership communication and cognitive linguistics. Dr. Sicola has spent over two decades transforming top-level executives into confident, inspiring leaders. Her unique approach, grounded in cognitive linguistics, empowers professionals to communicate their passion and expertise effectively, ensuring they get the buy-in they need for the results they want. Join us as we explore these topics and more, providing valuable insights for pharma professionals and anyone looking to enhance their executive communication skills. Dr. Sicola's expertise offers a roadmap to becoming a more effective and inspiring leader.
Chapters 00:00:00 - Introduction to WIFM: What's In It For Me? 00:00:34 - Real Pharma Podcast Introduction 00:01:02 - Introducing Dr. Laura Sicola 00:02:37 - Welcome and TEDx Talk Discussion 00:03:51 - Defining Linguistics 00:04:41 - Importance of How You Say It 00:05:52 - The Myth of Content vs. Delivery 00:07:01 - The Linguistic Glass Ceiling 00:09:06 - Transitioning from Technical Expertise to Leadership 00:11:04 - Your Work Speaks for Itself, But Not for You 00:12:24 - Developing Leadership Skills 00:13:07 - The Challenge of Self-Awareness 00:15:33 - Recording Yourself for Self-Diagnosis 00:17:16 - Impact of COVID on Communication 00:18:48 - Basic Skills for Effective Communication 00:20:14 - Executive Presentations: What's In It For Them? 00:23:05 - Seeking Constructive Feedback 00:25:27 - Common Reasons for Seeking Coaching 00:27:05 - The Expert's Curse 00:29:37 - The Gift of Clear Feedback 00:30:39 - Proactively Seeking Feedback 00:32:14 - Questions to Ask for Constructive Feedback 00:35:01 - The Importance of Diverse Feedback 00:36:20 - Communicating Complex Data Effectively 00:37:04 - The Role of Slide Design in Communication 00:40:13 - The Value of Interpretation and Insights 00:41:17 - Two Versions of PowerPoint: Pre-Read and Presentation 00:43:08 - The $200 is $200 Rule Resources Find Dr. Laura Sicola on: | |||
| Drug Importation Debate: Ilisa Bernstein on the Global Pill | 20 May 2024 | 00:51:25 | |
Summary Ilisa Bernstein, a senior Vice President at the American Pharmacists Association, discusses the history and current landscape of drug importation policies with a focus on Florida's program. Safety concerns, supply chain issues, and intellectual property rights are key considerations. The impact on the Canadian drug supply and the transparency of imported drugs for consumers are also discussed. Manufacturer concerns regarding rebates and discounts, as well as potential oversupply and export restrictions, are highlighted. The conversation explores the complexities and concerns surrounding drug importation programs. It discusses the mechanisms that manufacturers may use to control drug importation, such as restricting volume or increasing prices. The potential impact on the drug supply in Canada and the need for policies to protect it are also examined. The logistical challenges at the border and the vulnerabilities in the drug supply chain are highlighted. The importance of maintaining patient confidence in drug quality and the risks associated with personal drug importation are discussed. The conversation concludes by considering alternative solutions to lower drug prices and the inspiration drawn from historical figures.
Chapters 00:00 Introduction of Ilisa Bernstein 01:19 Background on Drug Importation 08:21 Safety Concerns 10:04 Supply Chain and Drug Source 14:58 Transparency and IP Issues 20:57 Consumer Transparency and NDC Numbers 21:10 Intellectual Property Concerns 22:59 Challenges and Points of Contention 25:12 Manufacturer Concerns: Rebates and Discounts 28:06 Oversupply and Export Restrictions 29:09 Mechanisms to Control Drug Importation 30:39 Policies to Protect Drug Supply in Canada 31:12 Logistical Challenges at the Border 33:07 Vulnerabilities in the Drug Supply Chain 35:03 Maintaining Patient Confidence in Drug Quality 36:31 Risks Before the Border 38:01 Complexities and Concerns for Community Pharmacists 41:31 The Future of Drug Importation Programs 44:00 The Motivation Behind Drug Importation Programs 46:01 Exploring Other Solutions to Lower Drug Prices 48:19 The Illegality of Personal Drug Importation 49:05 Balancing Cost Savings and Patient Safety 50:02 Inspiration from Historical Figures
Resources:
| |||
| Navigating Your Biopharma Career: A Masterclass with Recruiter Kristiaan Rawlings | 06 May 2024 | 00:49:17 | |
Summary In this episode, Kristiaan Rawlings discusses the 2024-2025 Commercial Market Update and Salary Guide produced by EPM Scientific. The life sciences sector remains resilient due to aging populations, scientific advances, and robust investment. Hiring practices and compensation are influenced by these factors across the Americas, Europe, and APAC regions. The hiring focus has shifted from life-threatening diseases to more common health issues, such as dermatology and respiratory diseases. The most in-demand roles include marketing, commercial operations (salesforce effectiveness, commercial analytics, and training), and sales. Market access roles have seen less demand. Despite the availability of talent, salaries have remained high or even increased. In this conversation, Kristiaan Rawlings discusses the current trends in the life sciences job market, specifically in the commercial operations field. He explains the increase in demand for talent, the impact of title deflation, and the rise in salaries. He also highlights the regional differences in job opportunities, with a shift towards the East Coast of the United States. Additionally, he touches on the importance of executive presence and the return of in-person networking events. Overall, the conversation provides valuable insights into the evolving landscape of the life sciences job market.
Chapters 00:00 High Demand for Marketing Roles 04:26 Focus on Core Areas with Existing Blockbuster Products 05:53 Sought-After Skills for Commercial Operations and Product Launches 13:54 Challenges with LinkedIn Applications and Fake Job Postings 24:25 Selective Market Based on Therapy Area and Experience 24:51 The Three Pillars of Focus: Salesforce Effectiveness, Commercial Analytics, and Training 25:21 High Demand for Talent in Incentive Compensation, Analytics, and Competitive Intelligence 26:17 Sales Roles in High Demand During Product Launches 26:46 Quiet Market in the Field of Market Access 27:14 Salaries Holding Strong or Increasing Despite High Supply of Talent 32:30 Geography Becoming Less of a Factor in Salary and Opportunity 41:08 High Demand for Medical Affairs and Health Economics 44:01 The Importance of Executive Presence and Networking for Career Success
Resources
| |||
| Pioneering Precision: Kira Dineen on Genetics’ Role in Tailored Therapies | 22 Apr 2024 | 00:53:11 | |
Summary In this episode, hosts Ian Wendt and Dr. Na-Ri Oh , and guest Kira Dineen discuss the intersection of genomics and healthcare. They explore the concept of personalized medicine and how advancements in genomics are revolutionizing healthcare. Kira shares her personal journey and the inspiration behind her DNA Today podcast. The conversation delves into the technology behind personalized medicine and the challenges of building comprehensive genetic databases. The ethical considerations of genomics, including access to information and the potential misuse of genetic data, are also explored. The episode concludes with a discussion on the need for ethical frameworks to keep pace with technological advancements in genomics. The conversation explores the controversial topic of gene editing, particularly the use of CRISPR technology. The hosts discuss the ethical considerations and the choice of genetic targets for editing. They also touch on the accessibility and long-term consequences of CRISPR. The conversation then shifts to the cost of treatment and the role of genetic testing in drug development. The potential of AI in genetic research is explored, as well as the future of personalized medicine. The episode concludes with a discussion on professional motivation and the importance of networking.
Chapters 00:00 Introduction to Kira Dineen and the Intersection of Genomics and Healthcare 02:07 Genomics and Personalized Medicine 04:13 Kira Dineen's Personal Journey and the DNA Today Podcast 08:08 The Trend Towards Personalized Medicine in Biopharma 10:11 The Technology Behind Personalized Medicine 12:39 Building Databases and Overcoming Barriers 15:18 Ethical Considerations in Genomics 20:39 Ethics and the Use of Genetic Information 24:06 Ethics Keeping Pace with Technological Advances 25:44 Managing Ethical Considerations in Genetic Research 27:21 Controversial Gene Editing 28:18 Choosing Genetic Targets 29:10 Ethical Considerations 29:44 Accessibility of CRISPR 30:13 Long-Term Consequences of CRISPR 32:51 Healthcare Equity and Cost of Treatment 34:25 Cost of Genomic Sequencing 35:22 Genetic Testing and Drug Development 38:13 Role of Genetic Testing in Clinical Trials 42:20 AI in Genetic Research 46:34 Future of Personalized Medicine 49:56 Professional Motivation and Networking
Resources:
| |||
| Venture Capital & Biopharma: Jim Trenkle on Pioneering Health Innovation | 08 Apr 2024 | 00:53:23 | |
Dive into the high-stakes world of Venture Capital in biopharma with Jim Trenkle! Have you ever wondered what it takes to turn groundbreaking scientific discoveries into life-saving treatments? What role do venture capitalists play in this thrilling journey from the lab to the clinic? This episode peels back the curtain on the biopharma venture capital scene, revealing the risks, rewards, and radical innovations driving the future of healthcare. Join hosts Dr. Na-Ri Oh and Ian Wendt as they explore with Jim the secrets of successful biopharma investments, the challenges of navigating the complex landscape of medical research funding, and the thrilling potential of the next big breakthroughs. Don't miss this conversation that could change the way you see medicine and innovation. In this episode, Jim Trenkle, a partner at Nova Holdings, shares insights on venture capital in the biopharma industry. He explains the different stages of investment, from seed rounds to IPOs, and the role of venture capitalists in providing capital and expertise. Jim discusses the current state of raising capital for biotech startups, including the impact of interest rates and market conditions. He also highlights the challenges and evaluation criteria in biotech VC, emphasizing the importance of a well-thought-out plan and addressing unmet needs. Jim Trenkle also discusses his own career path and the importance of finding work that has a deeper impact. He shares his journey from being a medicinal chemist to venture capital, highlighting the value of lifelong learning and broadening one's impact. Trenkle also discusses the challenges and skills required in venture capital, emphasizing the need for humility and the ability to make decisions that have a real impact. He reflects on the lessons learned from the Theranos scandal and the role of venture capitalists in evaluating companies. Trenkle explores the reasons behind company closures and failures in the biopharma industry and the potential for innovation and technological advances to shape the future of venture capital. He concludes with advice on career growth and the importance of following one's passion.
Chapters 00:00 Introduction of Jim Trankel
01:01 Understanding Venture Capital in BioPharma
07:59 The Current State of Raising Capital for Biotech Startups
11:23 The Landscape of Biotech Funding
16:25 Challenges and Evaluation in Biotech VC
23:16 What Does Good Look Like and Pitfalls to Avoid
31:19 Jim Trankel's Career Path
31:59 Career Path and Impact
35:19 Challenges and Skills in Venture
37:05 Evaluating Companies and Capital Allocators
38:23 Lessons from Theranos
46:01 Company Closures and Failures
52:42 The Future of VC in Biopharma
58:32 Advice and Mentors
Resources
| |||
| Decoding HEOR: Iris Tam’s Insights on Pharma’s Value-Based Future | 25 Mar 2024 | 00:49:26 | |
Join us on a deep dive into the world of Health Economics and Outcomes Research (HEOR) with the remarkable Iris Tam, PharmD, a luminary in value-based evidence generation within the biopharma industry. In this episode, our hosts Ian and Na-Ri explore with Iris the critical role of HEOR in transforming today's pharmaceutical landscape, from drug development to global marketing strategies and beyond.
Unpacking the complexities of HEOR, they delve into its definition, significance, and the evolving importance of this field in aligning drug development with payer expectations and patient outcomes. Iris shares invaluable insights on the key elements that payers scrutinize in HEOR studies, and the strategic considerations essential for successful global product launches.
Ethical considerations in HEOR research also take center stage, highlighting the responsibility of ensuring integrity and patient-centricity in evidence generation. For professionals eager to make their mark in HEOR or advance their careers, Iris offers sage advice, emphasizing the need for robust data, the value of learning from post-mortems, and the art of using failures to forge successful future strategies.
This episode is not just an exploration of HEOR's impact on healthcare but a guide to understanding the challenges of demonstrating product value and the crucial role of user adoption. Whether you're a seasoned professional or new to the field, Iris's journey and insights offer inspiration and guidance for navigating the complexities of HEOR in the biopharma industry.
Chapters
Resources:
| |||
| Redefining Fertility Care: Shelley Bailey’s Journey with Famlee | 10 Mar 2024 | 00:44:45 | |
Dive into the world of fertility with Shelley Bailey, the visionary founder and CEO of Famlee Fertility, on our latest episode. Discover Shelley's personal journey that led to the creation of Famlee, a company revolutionizing the fertility landscape with its home-based testing and clinical treatments aimed at empowering women to understand and enhance their fertility.
In this enlightening conversation, Shelley unravels the role of Famlee in supporting women through their fertility treatment journey, debunking common myths and misconceptions that surround fertility. Learn about the holistic approach and tailored treatment plans Famlee offers, designed to balance hormones and improve fertility from the comfort of home.
Tune in to gain valuable insights into overcoming fertility challenges, the importance of personalized care, and the future of fertility treatments. Whether you're navigating your own fertility journey or simply interested in the innovations transforming women's health, this episode promises to enlighten, inspire, and empower.
Chapters: 00:00 Introduction to Shelley Bailey and Famlee Fertility
04:02 Shelley's Personal Journey and Inspiration for Starting Famlee
09:47 The Role of Famlee in the Fertility Treatment Journey
14:38 Positioning Famlee in the Healthcare Landscape
17:10 Common Myths and Misconceptions about Female and Male Fertility
23:39 The Journey with Famlee: Holistic Approach and Treatment Plan
32:47 Challenges Faced as a Founder in the Fertility Sector
42:15 Future Plans and Expansion for Famlee
43:49 Mentors and Inspiration in Shelley's Entrepreneurial Journey
Resources:
https://opa.hhs.gov/adolescent-health/reproductive-health/understanding-fertility-basics
https://resolve.org/what-are-my-options/understanding-infertility/
https://www.mayoclinic.org/healthy-lifestyle/getting-pregnant/in-depth/fertility/art-20047584
https://us.fertility.com/female-fertility
https://www.yourfertility.org.au
| |||
| A Surgeon General’s Perspective: Dr. Adams on Health Innovation and Equity Challenges | 26 Feb 2024 | 01:03:53 | |
Dr. Jerome Adams, the 20th US Surgeon General, discusses various topics related to public health, including Operation Warp Speed, diversity in clinical trials, improving healthcare access and outcomes, addressing health inequities, collaborative approaches in healthcare, challenges with pricing models, the importance of prevention and health literacy, and lessons learned from COVID-19. In this conversation, Dr. Jerome Adams discusses the impact of political pandering on public health messaging and the erosion of trust in the CDC. He emphasizes the need for proper funding and communication in the CDC to effectively respond to public health crises. Dr. Adams also highlights the importance of practical information and listening to the public, as well as supporting public health workers. He suggests protecting the independence of CDC directors and Surgeon Generals to instill trust in the organization. The conversation also touches on the reputation of the pharma industry and the paradox of trust and distrust in public health organizations. Dr. Adams concludes by sharing his guiding principles of caring and finding common ground.
Takeaways
Chapters 00:00 Introduction to Dr. Jerome Adams
02:18 Discussion on Operation Warp Speed
05:34 Importance of Diversity in Clinical Trials
09:52 Improving Healthcare Access and Outcomes
18:03 Addressing Health Inequities
23:35 Collaborative Approach in Healthcare
25:30 Challenges with Pricing Models
30:21 Importance of Prevention and Health Literacy
35:06 Lessons Learned from COVID-19
45:57 The Impact of Political Pandering
46:53 The Perception of Political Leanings
47:40 The Erosion of Trust in the CDC
49:27 The Need for Proper Funding and Communication in the CDC
51:51 The Importance of Practical Information and Listening to the Public
53:25 The Importance of Supporting Public Health Workers
54:16 Protecting the Independence of CDC Directors and Surgeon Generals
55:47 The Reputation of the Pharma Industry
58:12 The Paradox of Trust and Distrust in Public Health Organizations
01:04:07 Guiding Principles: Caring and Finding Common Ground
Resources:
Operation Warp Speed Resources: | |||
| Advocacy in Action: Coy Stout’s Vision for Empowered Healthcare | 16 Feb 2024 | 00:52:56 | |
Trying to understand how pharma can effectively partner with patient advocates to support better patient outcomes? In this episode, Coy Stout discusses his journey in patient advocacy and the intersection of patient advocacy, policy, and social work in the pharma industry. He shares personal stories that motivated him to get involved in the field and highlights the importance of patient-centricity in biotech companies. Coy also discusses the role of technology in patient advocacy and the challenges and controversies surrounding patient advocacy in diseases like ALS and Alzheimer's. He emphasizes the need for transparency, collaboration, and patient input in decision-making processes, especially when it comes to drug pricing and access. In this episode, Coy Stout shares his insights on patient advocacy and the importance of patient-centered care. He discusses the challenges faced by patients and the need for more diverse representation in healthcare and pharma. Coy also highlights the transformative medicine happening now and the opportunity to bring real-world expertise into the industry. He envisions a future where patients and their caregivers are actively involved in guiding research and commercialization efforts. Overall, Coy emphasizes the importance of creating space for patients and their communities to contribute to innovation in healthcare.
Chapters: 00:00 Introduction 01:32 Motivation for Patient Advocacy 04:38 Early Relationships Between Advocacy Groups and Pharma 07:08 Patient-Centricity in Biotech Companies 09:42 Gold Standard of Patient Advocacy 10:51 Intersection of Patient Advocacy and DEI Initiatives 12:45 Engaging Employees in Advocacy 17:34 Role of Technology in Patient Advocacy 20:50 Controversies and Challenges in Patient Advocacy 31:07 Patient Advocacy in ALS and Alzheimer's Disease 38:00 Balancing Patient Advocacy and Drug Pricing 54:53 Closing Remarks
Links: Patient Advocate Foundation (PAF) offers various patient-friendly resources to empower individuals in leading their healthcare journey. These resources include publications, tip sheets, webinars, and interactive materials2.
The American Medical Association (AMA) is dedicated to advocating for patients’ access to quality healthcare. Physicians actively work to address health disparities and fight for patients’ rights through legislative efforts and legal support.
National Patient Advocate Foundation (NPAF): The NPAF provides additional resources to support patients in their healthcare experiences. | |||
| Bridging the Gap in Cancer Care Part1: Dr. Yaming Wang on Innovation, Access, and the Power of Knowledge | 03 Mar 2025 | 00:48:23 | |
🎙 RealPharma Podcast – Oncology Part 1: Understanding the Cancer Universe with Dr. Yaming Wang Cancer is one of the most complex and pressing challenges in modern medicine. But how much do we really understand about it? In this first episode of our two-part oncology deep dive, we sit down with Dr. Yaming Wang, founder of Alphabet Health, to break down the fundamentals of oncology and hematology. From the earliest discoveries in cancer research to today’s cutting-edge targeted therapies and immunotherapy, Dr. Wang shares his expertise on the science behind cancer, why it remains such a difficult disease to treat, and the role of communication in bridging the gap between innovation and patient care. 🔬 Topics we cover in this episode: ✔ The difference between solid tumors and blood cancers ✔ Why cancer is like its own universe in medicine ✔ How early detection and screening can make a difference ✔ The evolution of chemotherapy, targeted therapies, and immunotherapy ✔ Why science alone isn’t enough—effective communication is key Whether you're a biotech professional, healthcare communicator, or just curious about the latest in oncology, this episode is packed with insights you won’t want to miss. Resources: General Cancer Information & Education: 🔹 National Cancer Institute (NCI) – Comprehensive cancer research and education 🔹 American Cancer Society (ACS) – Trusted resource for cancer prevention, diagnosis, and treatment 🔹 World Health Organization (WHO) – Cancer Fact Sheet – Global insights on cancer trends and impact 👉 https://www.who.int/news-room/fact-sheets/detail/cancer Oncology Research & Innovations:🔹 American Society of Clinical Oncology (ASCO) – Latest breakthroughs in cancer treatment and clinical trials 🔹 National Comprehensive Cancer Network (NCCN) – Guidelines for cancer treatment and best practices 🔹 ClinicalTrials.gov – Find ongoing cancer clinical trials worldwide Cancer Screening & Prevention:🔹 CDC Cancer Prevention & Screening Guidelines – Know the recommended screening tests 👉 https://www.cdc.gov/cancer/dcpc/prevention/index.htm 🔹 Prevent Cancer Foundation – Focus on early detection and prevention strategies 👉 https://www.preventcancer.org Emerging Technologies & Future of Cancer Care:🔹 Caris Life Sciences – Liquid Biopsy & Precision Oncology 👉 https://www.carislifesciences.com 🔹 National Cancer Institute – Immunotherapy Research 👉 https://www.cancer.gov/research/areas/treatment/immunotherapy 🔹 AI in Oncology: How Artificial Intelligence is Changing Cancer Detection (Article from Nature) 👉 https://www.nature.com/articles/d41586-020-00847-2 #RealPharmaPodcast #Oncology #CancerResearch #Biotech #Pharma #MedicalInnovation #Immunotherapy #Healthcare | |||
| Engineering Health: Dr. Khalil Ramadi’s Vision of Bioengineering and Neuromodulation | 25 Jan 2024 | 01:00:30 | |
Dr. Khalil Ramadi, an assistant professor at New York University Abu Dhabi, discusses the field of bioengineering and his work in neuromodulation and ingestible electronics. He explains that bioengineering encompasses tinkering with biology and physiology, and its focus has shifted from building hardware tools for the clinic to devices that can be implanted in the body.
Dr. Ramadi's interest in neuromodulation stems from the need to improve brain technologies and find non-invasive ways to target specific areas of the body. He also explores the potential applications of neuromodulation in areas such as obesity, eating disorders, and diabetes. The challenges in bioengineering include regulatory issues, access to innovations, and the scalability of devices. In this conversation, Khalil Ramadi discusses the field of bioengineering and its potential impact on healthcare. He shares insights on the future of bioengineering education, emphasizing the need for innovation and commercialization.
Khalil also predicts advancements in personalized care and the potential for new technologies to diagnose and treat diseases. He highlights the importance of finding inspiration and overcoming challenges in the field. Lastly, he introduces Project Prana Foundation, a nonprofit organization focused on developing technologies for decentralized care. Chapters 00:00 Introduction to Dr. Khalil Ramadi 03:47 Defining Bioengineering 06:33 Dr. Ramadi's Journey into Bioengineering 10:30 The Role of a Bioengineer 11:56 Focus on Neuromodulation and Ingestible Electronics 16:41 The Gut-Brain Connection 17:26 Applications of Neuromodulation 20:38 Neuralink and the Future of Bioengineering 25:05 Neuromodulation and GLP-1 Agonists 29:27 Challenges in Bioengineering 33:33 The Future of Pharma and Bioengineering 36:18 Ensuring Access to Bioengineering Innovations 40:20 The FLASH Pill and Appetite Stimulation 47:02 The Future of Bioengineering Education 51:10 Predictions for the Next 10 Years 55:00 Finding Inspiration and Overcoming Challenges 58:31 Project Prana Foundation Resources Dr. Khalil Ramadi: https://www.linkedin.com/in/khalil-ramadi/
Ramadi Lab:
Ingestible electronics: Science Robotics paper for gastric stimulation: https://www.science.org/doi/10.1126/scirobotics.ade9676
Project Prana: https://www.projectprana.org/isave
Nano Robots Shrink Bladder Cancer: https://www.irbbarcelona.org/en/news/scientific/nanorobots-shrink-bladder-tumours-90
Light Powered Yeast: https://www.science.org/content/article/scientists-engineer-first-light-powered-yeast
DNA Detection Advances: | |||
| Beyond the Job Title: Mastering the Pharma Job Market with Kristiaan Rawlings | 25 Jan 2024 | 01:11:11 | |
This episode discusses the biopharmaceutical job market and the impact of the COVID-19 pandemic. It explores the state of the job market, including layoffs and hiring trends in the industry. The conversation also delves into the role of recruiters in the life sciences industry and provides insights into their day-to-day activities.
Additionally, it offers advice for candidates on how to approach working with recruiters and highlights the importance of building long-term relationships. The episode concludes with a discussion on the impact of technology on job applications. In this conversation, Kristiaan discusses the current hot areas in the industry, including GLP-1s, dermatology, neurology, ophthalmology, and respiratory. He also talks about the trend of title deflation and how candidates should focus on the responsibilities and long-term opportunities rather than just the title. Kristiaan provides insights into compensation trends, including base salaries, bonuses, and long-term incentives.
He also addresses the topic of work onsite vs. remote and how companies are expecting employees to be onsite two to three times a week. Finally, he shares advice on charting your path and being willing to do what others won't to achieve your goals. Chapters 00:00 - Introduction to the Biopharmaceutical Job Market 02:05 - State of the Job Market and Layoffs in the Biopharmaceutical Industry 03:31 - The Impact of the Great Resignation on the Pharmaceutical Industry 06:07 - The Influence of Disease Areas on Hiring Trends 08:30 - The Commercial Space in the Biopharmaceutical Industry 12:55 - A Day in the Life of a Life Sciences Recruiter 19:33 - Different Approaches and Business Models of Recruiters 24:51 - How Candidates Should Approach Working with Recruiters 27:49 - Building Long-Term Relationships with Recruiters 32:00 - Success Stories of Candidates Who Overcame Challenges 37:13 - The Impact of Technology on Job Applications 43:48 - Hot Areas in the Industry 48:23 - Title Deflation 57:26 - Compensation Trends 01:02:33 - Work Onsite vs. Remote 01:09:01 - Charting Your Path Resources | |||
| Navigating the Ethical Maze: Dr. Arthur Caplan on Bioethics in Modern Medicine | 25 Jan 2024 | 01:09:14 | |
Dr. Arthur Caplan, a distinguished bioethicist, discusses various topics related to bioethics. He highlights the importance of bioethics in areas such as organ transplantation, genetic testing, artificial intelligence, and personalized medicine. Dr. Caplan emphasizes the need for informed consent in research ethics and the importance of providing research participants with the results of studies. He also addresses the ethical considerations in organ transplantation, including the allocation of scarce resources and the role of living donors. Additionally, he discusses the ethical implications of expensive treatments and the allocation of limited resources in healthcare. The conversation explores the disparity in healthcare attention given to rare diseases compared to chronic conditions. It highlights the need for organized advocacy and lobbying for conditions that lack representation. The discussion also delves into the balance between investing in genetic therapies for rare diseases and preventive measures for chronic conditions. The ethical considerations of gene editing using CRISPR technology are examined, including the need for monitoring and surveillance of adverse effects. The potential for societal inequalities in access to gene editing is discussed, raising concerns about eugenics and the widening gap between those who can afford the technology and those who cannot. Chapters00:00 Introduction to Dr. Arthur Caplan 01:35 The Importance of Bioethics in Various Areas 09:25 Informed Consent in Research Ethics 17:29 Balancing Scientific Progress and Ethical Considerations in Human Subject Research 33:41 Ethical Considerations in Organ Transplantation 47:22 Healthcare Resource Utilization and Pricing 48:25 Disparity in Healthcare Attention 51:18 Balancing Rare Diseases and Chronic Conditions 53:36 Genetics vs. Environmental Intervention 58:26 CRISPR and Bioethical Concerns 01:05:13 Societal Inequalities in Access to Gene Editing 01:06:03 Inspiration from Ben Franklin Resources
| |||
| Trailer | 09 Dec 2023 | 00:02:47 | |
Coming January 2024! RealPharma Podcast is your gateway to the world of biopharmaceuticals and healthcare. Your hosts are two industry veterans who engage in in-depth conversations with pharma pathfinders/leaders who are shaping the future of medicine. Hear the stories behind the news that challenge traditional viewpoints and offer fresh perspectives that will make you rethink what you know about the healthcare industry. | |||
| The Future of Healing: Stem Cells, Regenerative Medicine & What’s Next | 10 Feb 2025 | 00:48:52 | |
In this episode of Real Pharma, hosts Na-Ri Oh and Ian Wendt engage with Joshua Kettner, co-founder of DreamBody Clinic, to explore the intricacies of stem cell therapy. They discuss the clinic's unique approach to regenerative medicine, the science behind mesenchymal stem cells, and the various applications and limitations of this therapy. The conversation also delves into the regulatory challenges faced in the US and how these impact the availability of such treatments. Kettner shares personal anecdotes and insights from his experience in the field, providing a comprehensive overview of the current landscape of stem cell therapy. In this conversation, Joshua Ketner discusses the complexities of stem cell therapy, including FDA regulations, economic challenges, and the importance of donor vetting. He highlights the risks and efficacy of treatments, the growing interest in longevity and anti-aging, and the vision behind his clinic's approach to regenerative medicine. The discussion emphasizes the need for better accessibility to these treatments for patients in need. Resources: | |||
| Psychedelic Renaissance: Insights from Ethnopharmacologist Dennis McKenna | 20 Jan 2025 | 00:55:53 | |
In this riveting episode of RealPharma, hosts Na-Ri Oh and Ian Wendt sit down with the renowned ethnopharmacologist, Dennis McKenna, to explore the profound intersection of nature, science, and healing. From Dennis’s storied journey into the world of plant medicines to the evolving landscape of psychedelic therapies, this conversation is as thought-provoking as it is inspiring. Key Topics Discussed: 🌿 Dennis’s Journey: How an early fascination with psychedelics and traditional practices shaped his career in ethnopharmacology. 🌌 Modern Psychedelic Science: The exciting potential of compounds like Ibogaine and psilocybin for treating addiction, PTSD, and neurodegenerative disorders. 🌍 Ethical Dimensions: The importance of honoring indigenous knowledge and the call for reciprocity in drug development. 🔬 Challenges in Biopharma: Why current regulatory frameworks struggle with psychedelics and how innovation can bridge the gap. 🎤 McKenna Academy's Mission: Insights into biodiversity preservation, education, and the Academy’s role in advancing plant medicine research. Notable Moments:
Resources: | |||
| Unlocking Pharma Career Success in 2025: Insights from Kristiaan Rawlings | 06 Jan 2025 | 00:45:22 | |
Year-End Wrap-Up with Kristiaan Rawlings In this episode of the Real Pharma Podcast, hosts Ian Wendt and Na-Ri Oh welcome back frequent guest Kristiaan Rawlings, a seasoned commercial pharmaceutical recruiter, for a year-end reflection on the pharmaceutical job market in 2024 and a look ahead to 2025. The discussion highlights key trends, challenges, and opportunities for candidates and employers alike. Key Highlights:
Resources: | |||
| Jason Scharf Explains How the Bio-Innovation Tech Stack Is Changing Everything | 16 Dec 2024 | 00:57:17 | |
In this episode of the Real Pharma Podcast, hosts Ian Wendt and Dr. Na-Ri Oh and guest Jason Scharf delve into the evolving landscape of TechBio, exploring its definition, the rise of bio innovation, and the challenges and opportunities it presents. They discuss the shift from traditional drug development methods to innovative approaches driven by technology, the importance of adapting business models in the pharmaceutical industry, and the need for a balanced regulatory framework that fosters innovation while ensuring safety. Jason shares insights on the future of drug development, the role of big pharma, and the necessity for a collaborative ecosystem to drive progress in healthcare. In this conversation, Jason Scharf discusses the evolving landscape of the TechBio sector, particularly in Austin, Texas. He highlights the intersection of science and policy, the growth of Austin as a tech bio hub, and the dynamics of the local ecosystem. Scharf emphasizes the importance of innovation, investment philosophy, and the future trends shaping the industry. He also shares personal insights on entrepreneurship and the significance of understanding one's skills and passions in driving change. Resources: | |||
| Radiopharmaceuticals: The Future of Precision Medicine with Roger Estafanos | 02 Dec 2024 | 00:50:42 | |
In this conversation, Roger Estafanos discusses the evolving field of radiopharmaceuticals, highlighting their transformative impact on cancer treatment and patient care. He explains the targeted nature of these therapies, the importance of personalized medicine, and the challenges faced in regulatory processes and patient safety. The discussion also covers the role of different radioisotopes, the complexities of supply chain management, and the need for improved access to these innovative treatments. The conversation delves into the complexities and advancements in the field of radiopharmaceuticals, focusing on logistics, future opportunities, investment landscapes, commercialization challenges, talent acquisition, and technological innovations. The speakers emphasize the importance of optimizing supply chains, the potential for expanding applications beyond oncology, and the role of AI in enhancing imaging processes. They also discuss the need for education among healthcare providers and patients, as well as the personal motivations driving their work in this evolving field.
Resources:
**Society of Nuclear Medicine and Molecular Imaging (SNMMI)** Comprehensive resource on the use of radiopharmaceuticals in imaging and therapy: [https://www.snmmi.org]
**Theragnostics Explained** An introduction to theragnostic approaches combining diagnostics and therapy: [https://www.cancer.gov/about-cancer/treatment/types/theragnostic]
**U.S. Nuclear Regulatory Commission (NRC)** Guidelines for handling, licensing, and safe administration of radiopharmaceuticals: [https://www.nrc.gov]
**FDA Guidance on Radiopharmaceuticals** Regulatory pathways and guidelines for the development of radiopharmaceuticals: [https://www.fda.gov]
**Patient Advocacy in Radiopharmaceuticals** Information for patients and caregivers about radiopharmaceutical therapies: [https://www.patientadvocate.org]
**Radiopharmaceutical Treatment Education** Tips and safety guidelines for patients undergoing radiopharmaceutical treatments: [https://www.cancer.net]
**AI in Radiopharmaceutical Imaging** How AI is transforming diagnostic imaging and patient care: [https://www.auntminnie.com]
**Global Radiopharmaceutical Market Reports** Market trends, forecasts, and analysis: [https://www.globenewswire.com] | |||
| Decoding Digital Marketing: Insights from Aaron Burnett | 18 Nov 2024 | 00:54:45 | |
In this conversation, Aaron Burnett, from Wheelhouse DMG, discusses the rapid evolution of digital marketing in the healthcare sector, emphasizing the importance of data strategy and compliance with regulations like HIPAA. He highlights the shift from third-party data reliance to first-party data utilization, which enhances marketing effectiveness and patient engagement. The discussion also covers the need for collaboration among marketing, compliance, and IT teams to develop effective data strategies and the role of customer data platforms in personalizing healthcare marketing efforts. In this conversation, the speakers delve into the complexities of data privacy, patient consent, and the ethical implications of using AI in healthcare. They discuss the transformative role of AI and machine learning in digital health, emphasizing the importance of first-party data and the need for compelling content. The conversation also touches on marketing strategies in a digital landscape, the evolution of media mix modeling, and the tools that enhance digital marketing efforts. Finally, the discussion concludes with an inspiring anecdote about unconventional thinking and the pursuit of personal fulfillment. Resources: | |||
| Rooted in Results: The Future of Functional Medicine with Dr. Erica Armstrong | 19 May 2025 | 00:49:25 | |
🎙 Episode Title: Rooted in Results: The Future of Functional Medicine with Dr. Erica Armstrong
🧬 Episode Summary In this episode, Dr. Na-Ri Oh and Ian Wendt sit down with Dr. Erica Armstrong, board-certified family medicine physician and founder of Root Functional Medicine, to explore the promise, challenges, and evolution of functional medicine. Dr. Armstrong discusses how Root’s systems-based, data-driven approach is helping patients uncover the root causes of chronic disease, improve outcomes, and reduce reliance on pharmaceuticals—all while scaling care with smart tech and telehealth. Whether you're in biotech, med affairs, or digital health, this conversation offers an eye-opening look into how patient-centric, preventative medicine could transform our approach to chronic disease—and what pharma can learn from it. 🧪 What You'll Learn:
🧵 Resources & Links Mentioned: 🔹 Guest Bio & Links
📘 Publications & Tools
💊 Related Guests Mentioned
💡 Topics Mentioned
📱 Follow the Hosts 🧠 Favorite Quotes 🗣 "Functional medicine is not more expensive than missed work, missed vacations, or endless procedures with no answers." – Dr. Erica Armstrong 🧪 "We start with conventionally trained MDs and pair them with dietitians to make the magic happen." 🧠 "Balanced blood sugar—protein, fat, and fiber—is the one thing I tell everyone to start with."
| |||
| The Future of Biotech | 02 Jun 2025 | 00:59:53 | |
🎙 Episode Title: The Future of Biotech
Guest: Andrew Craig, Founder of Plain English Finance | Author of Our Future is Biotech 📌 Episode Summary In this bold and wide-ranging conversation, Ian Wendt and Na-Ri Oh sit down with Andrew Craig—British investor, entrepreneur, and author—to explore how biotechnology is poised to shape the next century in the same way physics and computing shaped the last. Craig draws on his decades of experience as a London and New York investment banker and as a former partner at WG Partners, where he advised more than 60 biotech companies and worked on marquee deals like the $7.6B sale of Nordia Bank and IPOs for brands like EasyJet and Burberry. But his latest passion lies at the intersection of finance and innovation: making the case that our future is biotech—without a question mark. 🔍 Topics Covered
“The last century was about physics and tech. The next one will be about biology—and by extension, biotech.” “If success begets success, then a crop of billion-dollar biotech companies in Europe can kickstart a self-sustaining cycle of innovation and investment.” “People forget that the smartphone they hold was a $100 million science project in the 1990s. Biotech is heading the same direction.” “We need to fight the narrative that pharma is inherently bad. There are good actors, and we must do a better job telling those stories.” 📈 Key TakeawayBiotech isn't just a sector—it's a structural solution to some of humanity’s greatest problems. From disease treatment to environmental restoration, the converging forces of AI, genetics, and biological engineering make this the most consequential time in science since the industrial revolution.
| |||
| Hiring Heat Check: What’s Hot in Biotech + Pharma Talent in Mid-2025 | 16 Jun 2025 | 00:54:12 | |
Episode Title: “Hiring Heat Check: What’s Hot in Biotech + Pharma Talent in Mid-2025” 🎙️ Hosts: Ian Wendt & Na-Ri Oh 🎧 Guest: Kristiaan Rawlings, Executive Recruiter at EPM Scientific
Episode Overview: This week, fan favorite Kristiaan Rawlings returns to RealPharma to give us the raw and real insights on pharma and biotech hiring trends as we hit the midpoint of 2025. From compensation curves and BD boom times to the rise of GLP-1s and the return of oncology, this episode is your ultimate pulse check on where hiring is headed—and how to stand out in a crowded field.
Key Topics Covered: 🔹 BD & Search/Eval Roles in Overdrive Why demand is surging—and why having both scientific chops and business fluency makes you the unicorn every company wants.
🔹 Therapy Area Hot List Immunology, inflammation, liver disease (MASH), GLP-1s, and yes—oncology is back, baby.
🔹 Career Advice for Every Archetype Whether you’re a lifer from Big Pharma or a job-hopper with a story to tell, Kristiaan offers smart, tactical advice on how to pitch your value.
🔹 Hiring Manager Intel From pre-reads to leave-behinds to storytelling frameworks like STAR, we cover tools that actually make you memorable in interviews.
🔹 Sales Teams = Prizefighters? Kristiaan breaks down why commercial ops teams are like a boxer’s entourage—and why the whole team needs to hit harder in 2025.
🔹 Show Me the Money Real talk on compensation ranges from Director to SVP (spoiler: the market’s healthy), plus trends in title inflation/deflation.
Mentioned in This Episode:
Connect with Kristiaan Rawlings: 📩 Kristiaan on LinkedIn 🧪 Check out openings at EPM Scientific: https://www.epmscientific.com/jobs
Episode Highlights: “A 16-year tenure at one company? That’s a marriage. But now you’re dating again—and you need to know your story.” — Kristiaan Rawlings
📢 Subscribe to RealPharma Available on Spotify, Apple Podcasts, and wherever you get your dose of biopharma brilliance. 💬 Liked this episode? Let us know what roles or trends you'd like us to cover next time! | |||
| Paging Dr. ChatGPT with Bryce Sady | 30 Jun 2025 | 00:56:54 | |
Episode Title: Paging Dr. ChaptGPT with Bryce Sady AI Adoption in Healthcare: Navigating the Present and Shaping the Future with Bryce Sady Episode Description: On today's insightful episode of RealPharma, hosts Dr. Na-Ri Oh and Ian Wendt sit down with Bryce Sady, Vice President of Product Development at PSL Group's Medical Education and Communications Division, a veteran innovator at the intersection of healthcare data, education, and AI. Together, they dive into the fascinating landscape of artificial intelligence in healthcare and pharmaceuticals. From practical applications, barriers, and regulatory hurdles, to how clinicians and pharma professionals are integrating AI into their workflows, Bryce sheds light on current adoption rates and trends across the healthcare ecosystem. Key Highlights:
Bryce also shares his personal inspirations drawn from Tracy Kidder's powerful book, Mountains Beyond Mountains, reflecting on the importance of patient-centered perseverance in healthcare innovation. Who should listen? Healthcare professionals, medical educators, pharma marketers, digital health innovators, and anyone curious about the rapidly evolving role of AI in healthcare.
| |||
| 340B or Bust: Is This Program Failing the Sick | 14 Jul 2025 | 00:54:38 | |
🎙️ 340B or Bust: Is This Program Failing the Sick? This week on Real Pharma, hosts Dr. Na-Ri Oh and Ian Wendt dive into the tangled world of 340B with returning guest William “Bill” Sarraille—one of the most respected voices in healthcare law, an active patient advocate, and a rare disease patient himself. The 340B Drug Pricing Program was intended to help vulnerable patients by requiring drug manufacturers to provide discounted medications to covered entities. But as Bill puts it, has the program strayed too far from its patient-first mission? With explosive growth, patchwork state laws, opaque data, and billions on the line, is it still doing what it was designed to do—or are the sick paying the ultimate price? 🔍 In this episode, we explore:✅ How 340B ballooned from a modest program to a behemoth that may soon outpace Medicare Part D ✅ Why transparency remains elusive—and who’s resisting it ✅ The uncomfortable reality: charity care rates at major hospitals vs. billions in 340B profits ✅ The looming risks to rare disease innovation and patient access ✅ Bill’s insider perspective on why patients often aren’t seeing the savings ✅ What changes might be coming from state houses, courts, and possibly Washington Bill also shares candid insights from his own journey as a rare disease patient—and why that makes him both more hopeful and more skeptical than ever. 💡 Links & Resources Mentioned
| |||
| Behind the PBM Curtain: Antonio Ciaccia Exposes the Game | 28 Jul 2025 | 00:59:39 | |
Episode Title: Behind the PBM Curtain: Antonio Ciaccia Exposes the Game Show Notes: In this compelling episode of Real Pharma, hosts Na-Ri Oh and Ian Wendt welcome back Antonio Ciaccia, CEO of 46brooklyn Research and President of 3 Axis Advisors, for a hard-hitting discussion on the power and pitfalls of pharmacy benefit managers (PBMs). PBMs remain one of the most opaque and influential forces in healthcare—shaping drug prices, patient access, and payer negotiations—often under the guise of cost savings. Antonio, widely recognized as one of the most outspoken voices for transparency in the pharmaceutical supply chain, takes us deep inside the systemic problems that have led to distorted pricing models, misaligned incentives, and challenges for manufacturers, payers, and patients alike. Key Topics Covered:
Antonio also shares actionable insights for payers, manufacturers, and policymakers on how to realign incentives and reduce inefficiencies that inflate costs without adding value. Why Listen: If you work in pharma, healthcare policy, or benefit design—or simply want to understand why your medications cost what they do—this conversation is a must-listen. Antonio’s expertise cuts through industry jargon and exposes the real forces driving the drug pricing crisis. Resources & Links:
| |||
| From Rock Star to Rare Disease Revolutionary: Casey McPherson’s Fight for His Daughter’s Life | 11 Aug 2025 | 00:55:24 | |
Episode Title: From Rock Star to Rare Disease Revolutionary: Casey McPherson’s Fight for His Daughter’s Life In this deeply personal and inspiring conversation, hosts Na-Ri Oh and Ian Wendt sit down with Casey McPherson, founder and CEO of AlphaRose Therapeutics—and acclaimed recording artist—to explore how one father’s determination to save his daughter’s life is shaking up the rare disease drug development model. Casey shares his journey from fronting rock bands to founding a biotech company, sparked by his daughter Rose’s diagnosis with an ultra-rare genetic disorder. He discusses why the current rare disease model is broken, how Alpha Rose is reimagining the path from diagnosis to treatment, and the emotional and ethical complexities of innovating in this space. What You’ll Learn in This Episode:
Links & Resources:
| |||
| Can We Say That? Dara Katcher Levy on the AdPromo Regulatory Landscape | 25 Aug 2025 | 00:58:40 | |
In this episode of RealPharma, Ian Wendt and Na-Ri Oh sit down with Dara Katcher Levy, a regulatory attorney at Hyman, Phelps & McNamara, P.C.—widely regarded as one of the nation’s top firms in food and drug law. Dara brings decades of expertise in promotional review, labeling negotiations, and post-market compliance, helping life sciences companies navigate the complex world of FDA regulations. Together, they unpack the most pressing regulatory questions facing biopharma in 2025:
Dara also shares how she advises clients to balance responsible communication with compliance, and why she believes patients benefit from more information, not less, so long as it’s presented transparently and fairly. Resources & References
| |||
| Inside the CMC Black Box: A Deep Dive with Reza Oliyai | 08 Sep 2025 | 00:47:23 | |
🎙️ Episode Title: Inside the CMC Black Box: A Deep Dive with Reza Oliyai 🧾 Show Notes:What exactly is CMC — and why is it behind more FDA rejections than any other category? In this episode of RealPharma, hosts Na-Ri Oh and Ian Wendt sit down with Dr. Reza Oliyai, former SVP of Pharmaceutical & Biologics Operations at Gilead Sciences, and now Founder & CEO of Oliyai Consulting, to demystify the world of Chemistry, Manufacturing, and Controls (CMC). With over three decades of experience and a role in advancing 200+ drug candidates and 27 product launches, Reza offers a front-row seat to what goes wrong — and right — in the drug development journey. 🔍 In this episode, we explore:
“CMC is a black box to most executives. That’s a problem. Because it’s also the number one reason drugs get delayed.” — Dr. Reza Oliyai Whether you're in manufacturing, regulatory, executive leadership, or just trying to understand what actually gets a drug to market — this episode is a must-listen. 🔗 Resources & Mentions: 👤 About Our Guest:Dr. Reza Oliyai is a globally recognized leader in pharmaceutical operations, with deep expertise across small molecules, biologics, ADCs, peptides, siRNA, and more. After 28 years at Gilead Sciences, he now advises over 100 organizations worldwide through his firm, Oliyai Consulting.
| |||
| Building the Highway for AI in Pharma: A Conversation with Ilya Burkov | 22 Sep 2025 | 00:47:55 | |
🎙️ Episode Title: Building the Highway for AI in Pharma: A Conversation with Ilya Burkov 📍 Episode SummaryIn this episode of RealPharma, hosts Na-Ri Oh and Ian Wendt sit down with Dr. Ilya Burkov, Head of AI Cloud at Nebius, to explore the critical infrastructure enabling the AI revolution in drug development. While the headlines often focus on the promise of AI, Ilya brings us backstage—where the real acceleration happens. From GPU scalability and regulatory compliance to synthetic data and digital twins, this conversation unpacks how the roads, bridges, and power lines of cloud infrastructure are shaping the future of biopharma R&D. Whether you're a biotech founder, pharma executive, or AI enthusiast, this episode offers a 360° view into the unseen tech powering the next generation of therapies. 🧠 What You’ll Learn
🧭 Key Quote “Think of AI in pharma as the car. What we’re building is the highway—bridges, power, road signs—so researchers can just drive.” — Dr. Ilya Burkov 🧰 Resources & Mentions 👥 About the GuestDr. Ilya Burkov is Head of AI Cloud at Nebius, where he leads teams building cloud platforms purpose-built for AI workloads in life sciences. With a background in large-scale computing and a deep understanding of compliance in regulated industries, Ilya bridges the gap between bleeding-edge technology and real-world healthcare impact. 🎧 Listen & SubscribeFind RealPharma on your favorite podcast platform: Apple Podcasts | Spotify | Amazon Music 👉 Don’t forget to rate and review the show—it helps others discover the future of pharma!
| |||
| Where Policy Meets the Pharmacy Counter | 13 Oct 2025 | 00:55:13 | |
Where Policy Meets the Pharmacy Counter Featuring Congressman Jake Auchincloss Episode Summary In this episode of RealPharma, hosts Na-Ri Oh and Ian Wendt sit down with Congressman Jake Auchincloss (MA-04) to dissect the tangled web of policy, profit, and politics driving America’s drug pricing system. From pharmacy benefit managers (PBMs) to the politics of tariffs, this discussion explores the push for transparency, fair competition, and sustainable reform in healthcare. Auchincloss, a Marine veteran and member of the House Energy and Commerce Committee, brings a rare combination of policy depth and industry fluency. Together, they unpack how entrenched middlemen have distorted the system—and what bipartisan solutions could finally restore balance between innovation and access. What You’ll Learn:
Memorable Moments: “PBMs deserve to be bulldozed for their behavior over the last two decades.” “There’s no moral hazard in getting sick—no one fakes chemotherapy to get free drugs.” “The most expensive thing in the world is what hasn’t been invented yet.” Why It Matters: As drug costs rise and innovation races ahead, the U.S. faces a defining choice: will healthcare policy reward breakthroughs or bureaucracy? Congressman Auchincloss argues that reform is not just about prices—it’s about preserving America’s leadership in biomedical innovation while ensuring patients can actually access the medicines that save lives. Guest: Congressman Jake Auchincloss U.S. Representative for Massachusetts’ 4th District Member, House Committee on Energy and Commerce Hosts: Na-Ri Oh & Ian Wendt | |||
| Conversations, Not Campaigns: The Art of Authentic Engagement in Healthcare | 06 Oct 2025 | 00:52:51 | |
Episode Title: “Conversations, Not Campaigns: The Art of Authentic Engagement in Healthcare” 🗣️ Episode SummaryIn this episode, hosts Dr. Na-Ri Oh and Ian Wendt sit down with Colin Hung — healthcare technologist, marketing strategist, and co-founder of the long-running #HCLDR (Healthcare Leadership) Twitter community. Colin shares his journey from biomedical engineering to becoming one of the most respected community builders in digital health. Together, they explore what authentic engagement really looks like in the healthcare and pharma industries — from how companies can move beyond broadcasting to truly listening, to how AI can support rather than replace human connection in patient advocacy. 🧭 Key Themes & Takeaways
Colin Hung is a healthcare technologist, community strategist, and co-founder of the #HCLDR community. With more than 25 years in health IT, Colin has been a driving force in bringing together patients, clinicians, and innovators to discuss the future of care. He’s also a writer, speaker, and advocate for inclusive, patient-centered technology. 🔗 Connect with Colin:
🎧 Listen & Subscribe Find The RealPharma Podcast on: | |||
| From Job Search to Power Move: How Top Talent’s Playing 2025 | 27 Oct 2025 | 00:48:27 | |
🎙 Episode Title: From Job Search to Power Move: How Top Talent’s Playing 2025 🧠 Guests: Kristiaan Rawlings, Executive Director at EPM Scientific 🎧 Hosts: Na-Ri Oh & Ian Wendt Episode Summary Layoffs. AI. Resume black holes. The biopharma hiring market feels noisy—and not in a good way. But beneath the doomscrolling, there’s a more nuanced story unfolding. In this episode, Kristiaan Rawlings returns to RealPharma to deliver a data-backed pulse check on the state of hiring across the industry. Drawing from hundreds of hours of direct conversations with execs, talent leaders, and hiring managers, Kristiaan unpacks:
Whether you're job hunting, hiring, or just trying to read the market right—this conversation brings the clarity. Resources & Links 🔗 Connect with Kristiaan Rawlings on LinkedIn 🌐 Explore non-confidential roles at EPM Scientific | |||
| Food as Medicine: Promise, Pitfalls, and the Politics of the Plate | 10 Nov 2025 | 00:53:31 | |
👩🔬👨⚕️ Hosts:
Na-Ri Oh & Ian Wendt 🎧 Guest:Dr. Ron Shigeta – Biotech visionary, co-founder of IndieBio, and food innovation expert. 🧬 Episode Summary:In this deeply insightful and refreshingly candid episode, Ian and Nari welcome back biotech veteran Dr. Ron Shigeta to explore the evolving landscape where food, health, and biotech collide. From the collapse of the lab-grown meat hype cycle to the challenges of democratizing access to functional food, Ron brings hard truths, historical context, and cautious optimism to the table. As the U.S. federal government embraces its Make America Healthy Again (MAHA) agenda—reforming food policy to prioritize public health—the conversation asks: 👉 Can we finally treat food as medicine, and make it scalable, credible, and affordable? 👉 What went wrong with cultured meat—and what comes next? 👉 Why does Ron really hate the term “food tech”? If you’ve ever wondered whether the future of wellness lies in your fridge, your pharmacy, or your feed, this one’s for you. 🔑 Key Topics Covered:
“Technology for the public will always win—because once people use it, they can’t let it go.” – Ron Shigeta “We’ve invented healthcare Americans can’t afford.” – Ron Shigeta “Nobody buys food because it’s high-tech. Nobody. That’s not how trust is built.” – Ron Shigeta 📚 Mentioned in This Episode:
| |||
| Reinventing Cell Therapy with Acoustics | 24 Nov 2025 | 00:51:41 | |
Reinventing Cell Therapy with Acoustics, Microfluidics & High-Throughput Engineering
In this episode, hosts Na-Ri Oh and Ian Wendt sit down with Dr. Andrew Gray — immune cell engineer, biotech founder, venture capitalist, and CEO of CellEcho — to explore how a new acoustic-powered gene-delivery platform may redefine the boundaries of cell therapy. The conversation spans the current state of the cell therapy landscape, the persistent barriers to scalability, and why CellEcho’s ASOP platform (Acoustically Stabilized Oscillatory Pockets) could unlock a new era of faster, cheaper, and more effective cell engineering. 🔬 Episode Highlights 1. The State of Cell Therapy: Breakthroughs & Bottlenecks
CellEcho’s technology emerged from UC Irvine’s microfluidics program. By applying precision acoustic energy, the platform can:
This unlocks the ability to test dozens to hundreds of engineered CAR-T variants in days—rather than the years needed today. One academic lab spent 6 years evaluating 11 CAR-T variants. CellEcho tested 8 variants in under 48 hours — and aims for 100+ per week. 5. From Better Manufacturing to Better MedicinesWhile CellEcho originally targeted faster manufacturing, Andrew shares that the bigger opportunity is designing entirely better therapies, not simply making today’s ones faster. This includes:
Andrew shares how his mother's struggle with myasthenia gravis sparked his lifelong journey in immunology. His 20-year career investigating immune evasion, Tregs, and tumor microenvironments culminated in his conviction that next-generation cell engineering is essential. 7. What’s Next for CellEcho
Visit: https://cellechobio.com Contact: Via the Info link on the website (messages route directly to Dr. Gray). | |||
| Untangling the IRA with Emma Cousin | 08 Dec 2025 | 00:46:48 | |
🎧 Hosts: Na-Ri Oh & Ian Wendt 🎓 Special Guests: Emma Cousin (PhD Candidate, Choice Institute – UW), Amos Fung (RealPharma Intern & Student Pharmacist) 🔍 Episode Summary:In this thought-provoking episode, hosts Na-Ri Oh and Ian Wendt sit down with Emma Cousin, a PhD candidate at the Choice Institute, University of Washington, to unpack the real-world implications of the Inflation Reduction Act (IRA)—particularly the Medicare Drug Price Negotiation Program. Joining them is Amos Fung, a RealPharma intern who brings a front-line pharmacy perspective to the policy conversation. Together, they discuss:
| |||